arrow
J

Jack Khouri

cleveland clinic
H指数:22
被引数:1,936

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care

具有高危特征的多发性骨髓瘤在应用cilta-cabtagene autoleucel治疗后早期失败:对风险知情护理的启示

2026-10-220
OAAI
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026-07-270
OA
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

地塞米松用于管理接受塔尔奎他单抗治疗复发/难治性多发性骨髓瘤患者相关的细胞因子释放综合征

2026-06-150
OAAI
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapies.

社区社会经济劣势和距离治疗中心的距离不影响接受CAR T细胞疗法治疗的非霍奇金淋巴瘤和多发性骨髓瘤患者的生存结局。

2026-06-100
PRE
Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data

功能性高危表型预测多发性骨髓瘤的预后不良,且与一线治疗方案无关:CIBMTR数据的二次分析

2026-04-010
OAAI
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

elranatamab治疗多发性骨髓瘤的真实世界结局: 来自美国多发性骨髓瘤免疫治疗联盟的多中心分析

2026-03-270
OAAI
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma

系统性AL淀粉样变性伴发骨髓瘤中商业化BCMA靶向CAR T细胞疗法的安全性与有效性

2026-03-200
PREAI
Clinical Features of Systemic Amyloidosis: A Scoping Review

系统性淀粉样变性的临床特征:一项范围综述

2026-02-120
OAAI
The role of cardiac imaging for diagnosis of cardiac amyloidosis: a systematic review and meta-analysis of test accuracy

心脏成像在心脏淀粉样变性诊断中的作用:一项关于试验准确性的系统评价和荟萃分析

2026-01-010
PRE
Diagnostic Accuracy of Fat Pad Sampling and Bone Marrow Biopsy for AL Amyloidosis: A Systematic Review and Meta-Analysis

AL淀粉样变性脂肪垫取样和骨髓活检的诊断准确性:系统评价和Meta分析

2026-01-010
OA
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma

在复发/难治性多发性骨髓瘤中,塔克奎他单抗的浓缩型与标准型剂量递增方案比较

2026-01-010
PRE
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis

系统性AL淀粉样变性中双特异性T细胞衔接疗法的安全性与有效性

2025-11-010
PRE
Current management of non-amyloidosis monoclonal gammopathy of renal significance: Clinical features, treatment selections, responses and renal outcomes

非淀粉样变性肾损害意义单克隆丙种球蛋白病的当前管理:临床特征、治疗选择、疗效及肾脏结局

2025-10-230
OAAI
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response

多发性骨髓瘤患者对特克替玛初始无应答后延迟应答的预测因子

2025-10-110
OAAI
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists

复发难治性多发性骨髓瘤的管理:面向社区肿瘤科医师的循证指南

2025-09-270
PRE
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium

氟达拉滨淋巴细胞清除暴露与伊达比特-维克鲁塞尔治疗后复发性/难治性多发性骨髓瘤的毒性相关:来自美国骨髓瘤免疫治疗联盟的真实世界经验

2025-09-170
PREAI